A sudden FDA reversal on Moderna’s mRNA flu vaccine has raised concerns over potential conflicts of interest tied to Blackstone’s major investment. Critics question whether financial and political ties influenced regulatory decisions.
April 8, 2026
A sudden FDA reversal on Moderna’s mRNA flu vaccine has raised concerns over potential conflicts of interest tied to Blackstone’s major investment. Critics question whether financial and political ties influenced regulatory decisions.